Inclusion Criteria:

- Age 8- 65 years

- Diseases must be myelodysplastic syndrome and acute myelocytic leukemia

- Must need a bone marrow transplant

- Must have the ability to observe the efficacy and events

- Patient must have ability to understand and willingness to provide written informed
consent prior to participation in the study and any related procedures being
performed

Exclusion Criteria:

- Must not have uncontrolled intercurrent illness including ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or
psychiatric illness/social situations that would limit compliance with study
requirements

- Must not be pregnant or breastfeeding; pregnant women are excluded from this study
because decitabine is a Category D agent with the potential for teratogenic or
abortifacient effects; because there is an unknown but potential risk for adverse
events in nursing infants secondary to treatment of the mother with decitabine,
breastfeeding should be discontinued if the mother is treated with decitabine; these
potential risks may also apply to other agents used in this study

- Must not have a known or suspected hypersensitivity to decitabine